HRP20021023B1 - Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders - Google Patents

Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders

Info

Publication number
HRP20021023B1
HRP20021023B1 HR20021023A HRP20021023A HRP20021023B1 HR P20021023 B1 HRP20021023 B1 HR P20021023B1 HR 20021023 A HR20021023 A HR 20021023A HR P20021023 A HRP20021023 A HR P20021023A HR P20021023 B1 HRP20021023 B1 HR P20021023B1
Authority
HR
Croatia
Prior art keywords
lower alkyl
denotes
optionally substituted
halogen
sulfonyl
Prior art date
Application number
HR20021023A
Other languages
English (en)
Croatian (hr)
Inventor
Mutel Vincent
Wichmann Juergen
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20021023A2 publication Critical patent/HRP20021023A2/hr
Publication of HRP20021023B1 publication Critical patent/HRP20021023B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Virology (AREA)
HR20021023A 2000-06-30 2002-12-20 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders HRP20021023B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00113894 2000-06-30
PCT/EP2001/007135 WO2002002554A1 (en) 2000-06-30 2001-06-22 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
HRP20021023A2 HRP20021023A2 (en) 2004-08-31
HRP20021023B1 true HRP20021023B1 (en) 2006-08-31

Family

ID=8169121

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20021023A HRP20021023B1 (en) 2000-06-30 2002-12-20 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders

Country Status (35)

Country Link
US (2) US6589978B2 (xx)
EP (1) EP1299383B1 (xx)
JP (1) JP3994051B2 (xx)
KR (1) KR100529423B1 (xx)
CN (1) CN1178936C (xx)
AR (1) AR029288A1 (xx)
AT (1) ATE286895T1 (xx)
AU (2) AU8187701A (xx)
BR (1) BR0112093A (xx)
CA (1) CA2413243A1 (xx)
CZ (1) CZ2003280A3 (xx)
DE (1) DE60108394T2 (xx)
DK (1) DK1299383T3 (xx)
EC (1) ECSP024403A (xx)
ES (1) ES2234869T3 (xx)
HK (1) HK1058358A1 (xx)
HR (1) HRP20021023B1 (xx)
HU (1) HUP0301167A3 (xx)
IL (2) IL153425A0 (xx)
JO (1) JO2384B1 (xx)
MA (1) MA26923A1 (xx)
MX (1) MXPA02012270A (xx)
MY (1) MY126903A (xx)
NO (1) NO324218B1 (xx)
NZ (1) NZ523025A (xx)
PE (1) PE20020103A1 (xx)
PL (1) PL360396A1 (xx)
PT (1) PT1299383E (xx)
RU (1) RU2272026C2 (xx)
SI (1) SI1299383T1 (xx)
TW (1) TWI265928B (xx)
UY (1) UY26812A1 (xx)
WO (1) WO2002002554A1 (xx)
YU (1) YU99702A (xx)
ZA (1) ZA200209966B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
DE10240818A1 (de) * 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
GB0225938D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
EP1740570A2 (en) * 2004-04-05 2007-01-10 Schering Corporation Novel gamma secretase inhibitors
EP1758884A2 (en) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
AR050994A1 (es) 2004-06-30 2006-12-13 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas, y composicion farmaceutica en base al compuesto
JP2008507538A (ja) * 2004-07-22 2008-03-13 シェーリング　コーポレイション 置換アミドβセクレターゼインヒビター
ES2402362T3 (es) 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
RU2413510C2 (ru) * 2005-04-04 2011-03-10 Такеда Фармасьютикал Компани Лимитед Профилактический или терапевтический агент против депрессии или тревожного расстройства
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
ME00610B (me) 2005-08-30 2011-12-20 Takeda Pharmaceuticals Co 1 –heterociklilsulfonil, 2 –aminometil, 5– (hetero–) aril supstituisan 1–h–pirol derivati kao inhibitori lučenja kiseline
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101553481A (zh) * 2006-09-29 2009-10-07 格吕伦塔尔有限公司 取代的磺酰胺衍生物
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2010019903A1 (en) * 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
PE20141174A1 (es) 2008-08-27 2014-09-19 Takeda Pharmaceutical Compuestos de pirrol como inhibidores de la bomba de protones
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2351323B1 (es) * 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2351452B1 (es) * 2009-07-01 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
AU2022296214A1 (en) * 2021-06-25 2024-01-25 Albius Sciences Alpha Private Limited Heterocycloalkyl-substituted polyheteroazole derivative as medical drug for treatment and/or prevention of rs virus infectious disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905979A (en) * 1974-05-09 1975-09-16 Stanford Research Inst Diazabicyclooctanes and diazabicycloheptanes
US4539411A (en) * 1982-02-05 1985-09-03 Hoffmann-La Roche Inc. Rhodium complexes of chiral phosphines
US5036153A (en) * 1989-05-11 1991-07-30 Braish Tamim F Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
EP1033983A1 (en) 1997-11-24 2000-09-13 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US6645939B1 (en) * 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AT411339B (de) 1998-05-13 2003-12-29 Fronius Schweissmasch Prod Verfahren zum steuern eines schweissgerätes und steuervorrichtung hierfür
HUP0102532A3 (en) 1998-06-03 2002-06-28 Gpi Nil Holdings Inc Wilmingto Aza-heterocyclic compounds used to treat neurological disorders and hair loss and process for their preparation and pharmaceutical compositions containing them
BR9916328A (pt) 1998-12-18 2001-10-02 Schering Corp Inibidores de transferase de farnesila
HUP0201295A3 (en) * 1999-01-27 2002-10-28 Ortho Mcneil Pharm Inc Peptidyl heterocyclic ketones useful as tryptase inhibitors
TW575561B (en) * 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
ES2296618T3 (es) * 1999-05-20 2008-05-01 Dong Wha Pharmaceutical Industrial Co. Ltd. Derivados opticamente activos de acidos quinolin-carboxilicos que tienen sustituyentes de 7-pirrolidina que provocan actividad optica y un procedimiento para la preparacion de estos.
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors

Also Published As

Publication number Publication date
NZ523025A (en) 2004-04-30
PT1299383E (pt) 2005-05-31
AU8187701A (en) 2002-01-14
KR20030011378A (ko) 2003-02-07
NO324218B1 (no) 2007-09-10
US20030212066A1 (en) 2003-11-13
CN1178936C (zh) 2004-12-08
NO20026263L (no) 2002-12-27
IL153425A0 (en) 2003-07-06
YU99702A (sh) 2006-05-25
DE60108394D1 (de) 2005-02-17
HUP0301167A2 (hu) 2003-08-28
SI1299383T1 (en) 2005-06-30
NO20026263D0 (no) 2002-12-27
PE20020103A1 (es) 2002-02-13
HK1058358A1 (en) 2004-05-14
AR029288A1 (es) 2003-06-18
JP2004502688A (ja) 2004-01-29
US6589978B2 (en) 2003-07-08
MXPA02012270A (es) 2003-04-25
HRP20021023A2 (en) 2004-08-31
TWI265928B (en) 2006-11-11
AU2001281877B2 (en) 2006-08-31
JO2384B1 (en) 2007-06-17
PL360396A1 (en) 2004-09-06
JP3994051B2 (ja) 2007-10-17
DE60108394T2 (de) 2006-03-02
MY126903A (en) 2006-10-31
UY26812A1 (es) 2001-12-28
EP1299383A1 (en) 2003-04-09
HUP0301167A3 (en) 2009-12-28
ES2234869T3 (es) 2005-07-01
CN1440405A (zh) 2003-09-03
ECSP024403A (es) 2003-02-06
ZA200209966B (en) 2004-03-09
US20020019424A1 (en) 2002-02-14
RU2272026C2 (ru) 2006-03-20
DK1299383T3 (da) 2005-05-23
MA26923A1 (fr) 2004-12-20
WO2002002554A1 (en) 2002-01-10
CZ2003280A3 (cs) 2003-12-17
KR100529423B1 (ko) 2005-11-17
US6995182B2 (en) 2006-02-07
EP1299383B1 (en) 2005-01-12
BR0112093A (pt) 2003-05-13
CA2413243A1 (en) 2002-01-10
IL153425A (en) 2007-08-19
ATE286895T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
HRP20021023B1 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
HRP20000854B1 (en) Therapeutic biaryl derivatives
AU2001272476A1 (en) Piperidines for use as orexin receptor antagonists
HRP20020712B1 (hr) Farmaceutske strukture koje sadrže derivate azetidina, novi derivati azetidina i njihovo pripremanje
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
HRP20070529T3 (en) Imidazole derivatives as glutmate receptor antagonists
ES530902A0 (es) Procedimiento para preparar derivados de piperazina
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
YU67601A (sh) 1-arensulfonil-2-aril-pirolidin i derivati piperidina
FI842911A0 (fi) Dihydropyridiner som motverkar lokal blodbrist och foerhoejt tryck.
HRP20000508B9 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
MX9101236A (es) Procedimiento para la preparacion de compuestos azabiciclicos
SE8406302D0 (sv) New aminoguanidine derivatives and a process for the preparation thereof
EA200200611A1 (ru) Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции
DK400781A (da) Fremgangsmaade til fremstilling af 2-(1,4-benzodioxan-2-ylalkyl) imidazoler
WO1999021848A3 (en) Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
DE3674372D1 (de) 1,2,3,4,4a,9b-hexahydro-4a-aminoalkyldibenzofurane, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
AR019197A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA ANTIHISTAMINICOS, COMPUESTOS INTERMEDIOS, PROCEDIMIENTO DE PREPARACIoN DE DERIVADOS DE PIPERIDINA Y PROCEDIMIENTOS DE PREPARACIoN DE INTERMEDIARIOS.
EA200101209A1 (ru) Новые производные бензола, способ их получения и фармацевтические композиции, содержащие их
EA200500032A1 (ru) Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов
ES531933A0 (es) Un procedimiento para preparar un derivado de imidazolinona
EA200101050A1 (ru) Замещенные бензолактамные соединения
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
HRP20020347B1 (en) Phenyl-and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
EA200000598A1 (ru) Новые ингибиторы металлопротеазы, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070608

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20080623